A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.

NCT01290718 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped Slow recruitment

Conditions

Breast Cancer

Interventions

DRUG: capecitabine [Xeloda]
DRUG: trastuzumab [Herceptin]

Sponsor

Hoffmann-La Roche